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ABSTRACT Encephalomyocarditis virus (EMCV) is a picornavirus that produces lytic
infections in murine and human cells. Employing a genome-wide CRISPR-Cas9
knockout screen to ﬁnd host factors required for EMCV infection, we identiﬁed a role
for ADAM9 in EMCV infection. CRISPR-mediated deletion of ADAM9 in multiple hu-
man cell lines rendered the cells highly resistant to EMCV infection and cell death.
Primary ﬁbroblasts from ADAM9 KO mice were also strongly resistant to EMCV infec-
tion and cell death. In contrast, ADAM9 KO and WT cells were equally susceptible to
infection with other viruses, including the picornavirus Coxsackie virus B. ADAM9 KO
cells failed to produce viral progeny when incubated with EMCV. However, bypass-
ing EMCV entry into cells through delivery of viral RNA directly to the cytosol
yielded infectious EMCV virions from ADAM9 KO cells, suggesting that ADAM9 is not
required for EMCV replication post-entry. These ﬁndings establish that ADAM9 is re-
quired for the early stage of EMCV infection, likely for virus entry or viral genome
delivery to the cytosol.
IMPORTANCE Viral myocarditis is a leading cause of death in the United States,
contributing to numerous unexplained deaths in people 35 years old. Enterovi-
ruses contribute to many cases of human myocarditis. Encephalomyocarditis virus
(EMCV) infection causes viral myocarditis in rodent models, but its receptor require-
ments have not been fully identiﬁed. CRISPR-Cas9 screens can identify host depen-
dency factors essential for EMCV infection and enhance our understanding of key
events that follow viral infection, potentially leading to new strategies for preventing
viral myocarditis. Using a CRISPR-Cas9 screen, we identiﬁed a disintegrin and metal-
loproteinase 9 domain (ADAM9) as a major factor required for the early stages of
EMCV infection in both human and murine infection.
KEYWORDS a disintegrin and metalloproteinase 9 domain (ADAM9),
encephalomyocarditis virus, functional genomic screen
Encephalomyocarditis virus (EMCV) is a nonenveloped, single-stranded RNA (ssRNA)virus in the Cardiovirus genus of the Picornavirus family known to cause myocarditis,
diabetes, and neurologic and reproductive disorders in rodents and nonhuman pri-
mates (1). The virus was ﬁrst isolated in 1944 from a gibbon that died suddenly from
pulmonary edema and myocarditis (2) and later isolated from diseased pigs (3). Since
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its discovery, EMCV has been isolated globally in an extensive range of animal species
(4–7). Rodents, speciﬁcally rats, are believed to be the natural reservoir hosts of EMCV,
while infection of other animal species may result from occasional cross-species trans-
mission by ingestion of contaminated food, water, or infected carcasses (8–11). EMCV
has also emerged as a pathogen capable of causing large zoonotic pandemics and
decimating domestic animal populations, making it an important veterinary pathogen.
While human infections are rare, EMCV can cause symptomatic disease in humans,
manifesting as a mild, nonspeciﬁc febrile illness (12–15). Infection is more prevalent
among humans with occupational exposure to animals, particularly hunters (16–18),
suggesting a strong zoonotic potential for EMCV. While serious human EMCV infections
are generally rare, EMCV rapidly kills human cells such as HeLa cells as well as primary
human cells in culture (19, 20).
EMCV is a well-accepted and widely used model for studying mechanisms of
virus-mediated immune suppression, viral myocarditis, and insulin-dependent diabetes
(21–25). However, little is known about the receptor requirements of EMCV. The virus
receptor on host cells is often a key factor in inﬂuencing viral tropism for particular
tissues, which subsequently results in various disease manifestations of infection. Thus,
understanding viral pathogenesis often hinges on identifying the cellular molecules
that the virus binds to facilitate cell entry and subsequent infection. Here, we employed
a functional genomics approach to identify genes responsible for EMCV-induced lytic
infection in both human and murine cells. Using a genome-wide CRISPR-Cas9 screen,
we identiﬁed ADAM9 as a major EMCV dependency factor (EDF). ADAMs (a disintegrin
and metalloproteinase domain) are a family of transmembrane metalloproteinases that
play important roles in growth factor and cytokine signaling as well as cell-cell
signaling, adhesion, and extracellular matrix remodeling (26–35). In animals, including
humans, ADAM9 is ubiquitously expressed in cells of the developing heart, brain, retina,
lung, ﬁbroblasts, neutrophils, and platelets (27, 30, 34–50). Approximately half of the
ADAM family members, including ADAM9, have proteolytic capabilities that modulate
the activity of cytokines, chemokines, and growth factors; their associated receptors;
and cell adhesion molecules (27, 35, 37, 45). ADAMs have been implicated in a range
of human cancers, inﬂammatory diseases, wound healing, and microbial infections;
however, very little is known about the role of ADAMs in viral infection. This study
demonstrates that ADAM9 functions as a major EDF involved in the early infection of
both human and murine cells.
RESULTS
CRISPR-Cas9 screening identiﬁes EMCV dependency factors (EDFs). EMCV in-
fection is rapidly lytic in human and murine cells (51–54). We took advantage of the
high lytic potential of EMCV and the power of CRISPR genetic screening (53, 55) to
discover virus-host interaction genes that mediated virus infection and, thus, rendered
the cells susceptible to EMCV-induced cell death. HeLa cells stably expressing Cas9
were used for screening (53, 55). In initial optimization experiments, we determined
that HeLa cells were killed by EMCV within 24 h of infection at a multiplicity of infection
(MOI) of0.1. The rapid lysis of HeLa cells with EMCV infection allowed us to screen for
EDFs using pooled single-guide RNAs (sgRNAs) since we could identify such mutant
cells by their resistance to EMCV-induced cell death, i.e., these mutants would no longer
be susceptible to EMCV infection and would survive EMCV challenge.
We screened for EDFs using a CRISPR-Cas9 pooled human gene screen (Fig. 1).
H1-HeLa cells (stably expressing a human-codon optimized Streptococcus pyogenes
Cas9) were transduced with the GeCKOv2 sgRNA library (53, 54), a complex lentiviral
library that targets 19,052 human genes. The GeCKOv2 library contains six unique
sgRNAs per gene in two half-libraries (A and B). Libraries A and B each contain three
unique sgRNAs per gene, and the lentiviral libraries were transduced in parallel into
H1-HeLa cells. Stable sgRNA-expressing cells were selected with puromycin for 48 h to
allow sgRNA-guided CRISPR-Cas9-mediated gene deletion within each pool. The
CRISPR-Cas9-sgRNA-transduced H1-HeLa cells were then infected with EMCV ATCC
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strain VR-129B (MOI of 10). Surviving cells in each pool (5% of the starting population)
were collected 5 days postinfection, rechallenged with EMCV, and cultured for an
additional 7 days (Fig. 1A). After two rounds of EMCV selection, genomic DNA was
recovered from the surviving cells and sgRNA sequences were ampliﬁed from inte-
grated proviruses by PCR and deep sequenced as described previously (53).
The screen was performed twice, and seven candidates (ADAM9, PA2G4, C1GALT1C1,
C1GALT1, SLC39A9, TMEM165, and CELF1) were highly enriched in replicate pools
FIG 1 CRISPR-Cas9 knockout screen for EDFs. (A) HeLa cells expressing Cas9 were transduced with the
GeCKOv2 sgRNA library, and guide sequences were retrieved from cells that survived multiple rounds of
EMCV infection. (B) ADAM9 sgRNA sequences were highly represented in recovered clones; 6 of the 6
sgRNAs targeting ADAM9 were present in recovered clones. GeCKOv2 screen results for genes conferring
susceptibility to EMCV-induced cell death. Of the pooled CRISPR-targeted genes, ADAM9- and PA2G4-
targeted guide sequences accounted for 70% and 22%, respectively. (C) Domain structure and sites
targeted by sgRNAs.
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(Fig. 1B). The top candidate in each pool in replicate experiments was ADAM9, with 6
of 6 sgRNA sequences targeting ADAM9 being signiﬁcantly enriched (600 reads)
(Fig. 1B). ADAM9 sgRNAs were highly enriched in both library A and library B pools.
Overall, ADAM9 sgRNAs accounted for 70% of the overrepresented (20 reads)
sgRNAs recovered from EMCV-resistant cells. The second most abundant candidate was
PA2G4, which accounted for 22% of the overrepresented sgRNAs. ADAM9 belongs to
the ADAM family of type I transmembrane proteins in the zinc-dependent metallopro-
teinase (MP) superfamily and is comprised of 6 different domains each with distinct
functions: (i) a prodomain that maintains the MP domain in latent form; (ii) an MP
domain; (iii) a disintegrin domain, which binds integrins to regulate cell-cell or cell-
matrix interaction and/or cell migration; (iv) a cysteine-rich and epidermal-like growth
factor (EGF) domain, thought to promote cell-cell fusion and/or regulate cell adhesion;
(v) a transmembrane domain, which anchors to the cell surface; and (vi) a cytoplasmic
tail involved in intracellular signaling (Fig. 1C).
ADAM9 is required for EMCV-induced cell death and virus replication in human
and murine cells. To determine the role of ADAM9 in EMCV infection, we used
CRISPR-Cas9 and ADAM9-speciﬁc sgRNAs to disrupt ADAM9 expression in HeLa and
HEK293T human cell lines. WT and ADAM9-deﬁcient cloned cells were tested for their
susceptibility to EMCV-induced cell death by assessing cellular ATP levels in a luciferase-
based assay as a measure for cell viability. ADAM9 KO clones were resistant to EMCV
infection compared to their WT counterparts (Fig. 2). WT and ADAM9 KO cells were
challenged with EMCV over a range of MOIs, and cell viability and EMCV replication
were measured after 24 h (Fig. 2). WT HeLa cells were sensitive to EMCV-induced cell
death at MOIs of 0.1 (Fig. 2A). In contrast, ADAM9 KO HeLa cells were protected from
EMCV-induced cell death even at MOIs of 10. At an MOI of 1, ADAM9 KO HeLa cells were
99% viable while 1% of WT HeLa cells survived EMCV challenge. We also examined
EMCV-induced cell death in HEK293T cells (Fig. 2C). WT HEK293T cells were very
sensitive to EMCV-induced cell death at all MOIs, with 5% survival of cells at doses as
low as an MOI of 0.001. In contrast, ADAM9 KO HEK293T cells survived EMCV challenge
at doses up to an MOI of 10. Thus, loss of ADAM9 expression rendered HEK293T cells
6 logs less sensitive to EMCV-induced cell death than WT cells. We conﬁrmed the role
of ADAM9 in EMCV infection by measuring virus replication by plaque assays of culture
supernatants. Replication of EMCV was markedly reduced in ADAM9 KO compared to
WT cells, suggesting that ADAM9 might be required for EMCV binding and/or entry or
post-entry transcription of the viral genome (Fig. 2B and D).
We next asked if ADAM9 was required for EMCV infection of primary murine cells.
Primary lung ﬁbroblasts (pLF) frommice with targeted deletion of ADAM9 (43) and their
WT C57BL/6 counterparts were challenged with EMCV. WT pLF were susceptible to
EMCV-induced cell death (Fig. 2E) and produced high titers of EMCV (Fig. 2F). In
contrast, ADAM9 KO pLF were highly resistant to EMCV killing and were unable to
support EMCV replication. At the highest MOI tested, ADAM9 KO pLF demonstrated
some limited EMCV replication, but production of infectious EMCV virions was severely
attenuated with an approximately 4-log decrease in infectious virion production (PFU)
by ADAM9 KO compared to WT cultures. These results suggest that murine ADAM9, like
human ADAM9, plays a major role in EMCV-speciﬁc lytic infection of cells.
The requirement for ADAM9 in EMCV-induced cell death is not strain speciﬁc.
Previous EMCV studies suggest that different strains of EMCV may bind to different
receptors and that some EMCV strains may use multiple pathways (56, 57). In addition,
EMCV strains with different tissue tropism have been identiﬁed (1). To determine if the
requirement for ADAM9 was EMCV strain speciﬁc, we infected WT and ADAM9 KO
immortalized mouse lung ﬁbroblasts (iLF) either with EMCV VR-129B (ATCC) or with
EMCV-M strain (VR-1479, ATCC). ADAM9 KO cells were resistant to both EMCV strains,
while WT cells were susceptible (Fig. 3A and B). We also tested if ADAM9 deﬁciency had
an impact on replication of other RNA and DNA viruses. WT and ADAM9 KO HeLa cells
were challenged with Coxsackie virus B3 (CVB3), vesicular stomatitis virus (VSV), inﬂu-
enza A virus (IAV), or herpes simplex virus 1 (HSV-1). WT and ADAM9 knockout cells
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were equally susceptible to infection with CVB3, VSV, IAV, and HSV-1 (Fig. 3C to F). Cells
infected with VSV showed equal yields of infectious VSV from WT and ADAM9 KO pLF
(Fig. 4C), suggesting that ADAM9 deﬁciency did not globally impact RNA virus repli-
cation.
FIG 2 ADAM9 is a major dependency factor for EMCV infection of human and mouse cells. WT and
ADAM9 KO HeLa cells (A and B) and HEK293T cells (C and D) and two independent sets of primary lung
ﬁbroblasts (pLF) isolated from WT and ADAM9 KO mice (E and F) were incubated in medium alone or
infected with EMCV at various multiplicities of infection (MOI) for 1 h at 37°C, washed to remove free
virus, and cultured for 24 h at 37°C. Cell viability (A, C, and E): ATP was quantiﬁed in the cell monolayers
using CellGlo reagent, revealing that ADAM9 KO cells are highly resistant to EMCV-induced cell death.
Virus replication (B, D, and F): EMCV viral titers, measured on BHK21 monolayers and expressed as PFU
per ml cell supernatant, showed only small amounts of replicating virus in ADAM9 KO cells. Cell viability
data are mean  SD from 3 replicate wells; plaque assay data are mean  SD from 2 replicate wells at
each dilution. Biological replicate experiments were performed at least twice with similar results.
ADAM9 Regulates EMCV Infection ®
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ADAM9 is essential for EMCV infection but is not directly involved in post-entry
replication of viral genomes in the cytosol. To determine whether ADAM9 is
required for virus binding/entry and/or required at a later step in virus replication
post-entry, we transfected infectious EMCV viral RNA (vRNA) into iLF using Lipo-
fectamine, thus bypassing the requirement for receptor-dependent entry events. iLF
were either infected with intact EMCV virions for 1 h at 37°C, washed to remove residual
free virus, and cultured for 18 h at 37°C (Fig. 4A) or transfected with EMCV vRNA in
Lipofectamine and incubated at 37°C (Fig. 4B). iLF were also infected with VSV, as a
positive control, for 1 h at 37°C, washed, and cultured (Fig. 4C). After 18 h, culture
supernatants were harvested, and viral replication was determined by quantifying
infectious virions in culture supernatants by plaque assay. EMCV infection of WT cells
FIG 3 ADAM9 is required for EMCV infection but does not affect infection by other RNA or DNA viruses. WT and
ADAM9 KO cells, including immortalized lung ﬁbroblasts (iLF) and HeLa cells, were challenged with EMCV VR-129B
(A), M-variant VR-1479 (B), Coxsackie virus B3 (CVB3) (C), vesicular stomatitis virus (VSV) (D), inﬂuenza A virus (IAV)
(E), or herpes simplex virus 1 (HSV-1) (F) at various MOIs or incubated in medium alone for 1 h at 37°C. Cell
monolayers were washed to remove free virus and incubated for 24 h at 37°C. Viability of infected cells relative to
uninfected (medium-only) controls was determined with a CellGlo ATP assay and is expressed in relative luciferase
units (RLU). Data are mean  SD from 3 replicate wells. Biological replicate experiments were performed at least
twice with similar results.
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resulted in productive infection of cells (at least 8 logs within 18 h), while infection of
ADAM KO cells resulted in no virus production (Fig. 4A). When receptor-mediated cell
entry is bypassed by transfection of infectious vRNA directly into the cell, EMCV is
capable of replicating in both WT and ADAM9 KO cells (Fig. 4B). Together, these results
demonstrate that ADAM9 is not directly involved in EMCV replication steps post-entry
but rather facilitates EMCV entry and/or genome delivery into the cell where EMCV
vRNA genomes are replicated in an ADAM9-independent manner.
Rescue of ADAM9 in KO cells restores susceptibility to EMCV.We next examined
if rescue of ADAM9 expression to ADAM9 KO cells restores EMCV susceptibility. ADAM9
KO and WT HeLa and mouse iLF cells were transduced with retroviral vectors to express
murine ADAM9 (mADAM9) or GFP as a control. Transduced cells were selected and
cloned by limiting dilution. Expression of ADAM9 was conﬁrmed by Western blot
analysis (Fig. 5A). ADAM9 KO cells rescued with intact wild-type (WT) mADAM9 became
susceptible to EMCV-induced cell death (Fig. 5B), demonstrating that ADAM9 is both
necessary and sufﬁcient to confer EMCV susceptibility.
ADAM9 is a multifunctional protein and has several domains that participate in a
variety of cell processes. ADAM9 controls receptor-mediated signaling via the proteo-
lytic function of its MP domain and signals via its SH3 domains in the cytoplasmic tail.
To determine if mutating the MP domain of ADAM9 impacts susceptibility to EMCV, we
rescued ADAM9 KO cells with an enzyme-dead mutant ADAM9 containing a Glu-to-Ala
(EA) substitution in the MP active site (58). The MP mutant ADAM9 restored EMCV
susceptibility to KO cells (Fig. 5B and C). Thus, EMCV susceptibility in KO cells rescued
with (EA) mutant was indistinguishable from rescue with WT ADAM9, indicating that
the active MP domain is not required for EMCV entry into cells. We next asked if the
intracellular signaling domain of ADAM9 was necessary to render cells susceptible to
EMCV. We replaced the cytosolic domain of ADAM9 with a V5-epitope tag and
expressed the cytoplasmic-tail-deleted (ΔCT) mutant in KO cells (Fig. 5B and C). EMCV
susceptibility was restored with ADAM9-ΔCT rescue, suggesting that the cytoplasmic
tail of ADAM9 does not play a role in EMCV susceptibility.
We also challenged WT, ADAM9 KO, and rescued KO cells with various doses of
CVB3. As shown in Fig. 5B, we did not observe any differences in susceptibility to CVB3
infection in WT, KO, and rescued cells, conﬁrming that ADAM9 is speciﬁcally required
for EMCV infection.
DISCUSSION
Forward genetic screens allow an unbiased and comprehensive approach to dis-
covering host factors that promote or restrict virus replication. Recent advances in
CRISPR-Cas9 have allowed highly efﬁcient generation of knockout cells with marked
FIG 4 ADAM9 is required for EMCV infection but is not directly required for genome replication in the cytosol. WT and ADAM9
KO immortalized lung ﬁbroblasts (iLF) were incubated with EMCV for 1 h at 37°C and washed (A), transfected with EMCV viral RNA
(vRNA) in Lipofectamine (B), or incubated with VSV (C). Culture supernatants were harvested after 18 h. Virus replication was
measured by quantifying PFU on BHK-21 cells. Data shown are mean  SD from 3 replicate wells. ***, P  0.0001, WT versus
ADAM9 KO.
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phenotypes for the identiﬁcation of virus dependency factors with very few false-
positive hits. CRISPR-Cas9 screens using multiplexed pools of sgRNAs that cover the
entire human genome have proved to be a powerful technologic advance and have
been successfully used to identify receptors and other cellular dependency factors for
several viruses, including inﬂuenza A virus, Zika virus, West Nile virus, dengue virus, and
hepatitis C virus (53, 54, 59–61; reviewed in reference 55).
In the present study, we employed a genome-wide CRISPR-Cas9 screen to identify
EDFs. The screen recovered multiple host factors, including those involved in the
posttranslational modiﬁcation of cell surface proteins (C1GALT1C1, C1GALT1, TMEM165),
cellular proliferation (PA2G4), the regulation of mRNA processing (CELF1), and the
FIG 5 Rescue of ADAM9 expression restores EMCV replication in ADAM9 KO cells. WT and ADAM9 KO HeLa
cells were transduced with retroviral vectors with wild-type (WT) murine ADAM9 (mADAM9), catalytically
inactive mutant ADAM9 (EA), cytoplasmic-tail-deleted (ΔCT) ADAM9 constructs, or GFP control vectors.
(A) WT, KO, and rescue cell lysates were analyzed by Western blot using two different ADAM9 antibodies.
Top panel, rabbit anti-human ADAM9 that detects an epitope in the intracellular domain of human ADAM9
and cross-reacts with mouse ADAM9 (black asterisk). Middle panel, goat anti-mouse ADAM9 that detects
the extracellular domain of murine ADAM9 but not human ADAM9 (blue asterisk). Bottom panel, anti-actin
which detects both human and murine -actin. Top panel, WT but not KO cells expressed human ADAM9.
Middle panel, rescue but not KO cells expressed murine ADAM9. Bottom panel, actin loading control. (B)
WT clones, ADAM9 KO clones, and rescued ADAM9-expressing clones were infected with EMCV or CVB3 at
various MOIs and incubated at 37°C for 24 h. Viability of EMCV-infected and CVB3-infected clones was
measured by CellGlo ATP luminescence. (C) EMCV replication was quantiﬁed in infected culture superna-
tants by plaque assay. Neither the functional sequence of the ADAM9 metalloproteinase domain nor the
cytoplasmic tail is required for EMCV infection. ***, P  0.0001, KO versus WT and KO versus rescue.
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metalloproteinase ADAM9. We focused on ADAM9 because it was the most strongly
enriched candidate in the screen and scored with multiple orthologous sgRNAs. Using
a diverse panel of CRISPR-engineered ADAM9 KO human cell lines, as well as primary
and immortalized murine cell lines from ADAM9 KO mice, we conﬁrmed ADAM9’s
involvement in EMCV infection and demonstrated that loss of ADAM9 results in a
profound block to the early stages of EMCV infection. To our knowledge, this study is
the ﬁrst to deﬁne a direct role for ADAM proteins in EMCV infection.
Previous studies have suggested different proteins that may be involved in suscep-
tibility to EMCV, but deﬁnitive proof (including reconstitution of knockout cells) has not
been forthcoming. For example, vascular cell adhesion molecule 1 (VCAM-1), a member
of the immunoglobulin superfamily, found on primary vascular endothelial cells has
previously been reported as a receptor for the EMC-D strain (62). However, cells lacking
VCAM-1 have also been shown to be susceptible to EMCV infection via a yet-
uncharacterized 70-kDa glycoprotein hypothesized to be responsible for mediating
virus binding and attachment in these cells (56). Infection of human cardiomyocytes
with two different strains of EMCV demonstrated a requirement for sialic acid and
heparan sulfate in one EMCV strain but not the other, raising the possibility that
different EMCV strains may bind to different polysaccharides in order to initiate
infection (57). While different molecules have been implicated as receptors or attach-
ment factors for speciﬁc strains of EMCV, the provenance of these strains has been
difﬁcult to authenticate, and we have not been able to obtain many of the strains
previously reported to have speciﬁc receptor or attachment requirements. However, in
this study, we were able to conﬁrm that the two ATCC strains of EMCV both use ADAM9
as their major dependency factor. ADAM9 is likely the 70-kDa putative EMCV receptor
identiﬁed by Jin et al. (56). Furthermore, we showed that the dependency on ADAM9
for infection is unique to EMCV, as infection with other RNA and DNA viruses was not
affected by ADAM9 deﬁciency. Thus, although previous studies have identiﬁed certain
cell surface molecules as potential EMCV receptors or EDFs, this is the ﬁrst report of a
deﬁnitive, widely expressed cell surface protein utilized by multiple EMCV strains that
is critical for EMCV infection. Future experiments will be necessary to deﬁne the role of
ADAM9 and other cell surface proteins as binding or entry receptors or receptor
cofactors for EMCV variant strains, as the use of alternative receptors or attachment
proteins may impact tissue tropism and ultimately EMCV pathogenesis.
ADAMs have been shown to regulate receptor signaling through a variety of
mechanisms, many of which involve the catalytically active MP domain (27, 28, 30, 31,
33, 35, 42, 63–65). This raises the possibility that ADAM9 may function as a cofactor for
EMCV infection. Given the multifunctional domains of ADAMs, it is also possible that
ADAM9 plays a role in the immune response to EMCV infection following virus entry,
for example, by delivering the viral genome to intracellular innate immune sensors,
triggering an appropriate antiviral response. Alternatively, it is also possible that
ADAM9 may be involved in innate immune evasion by EMCV, such as allowing EMCV
to enter the cell undetected or by skewing the innate antiviral signaling pathways. Of
ADAM9’s multiple domains, we initially hypothesized that the enzymatically active MP
domain and the intracellular cytoplasmic domain containing SH3 binding domains
might be involved in EMCV infection. However, our rescue experiments showed that
neither the metalloproteinase activity nor the cytoplasmic tail of ADAM9 is necessary to
support lytic EMCV infection. Furthermore, the ﬁnding that EMCV infection does not
require a catalytically active proteinase domain suggests that ADAM9 may not act as a
proteolytic cofactor and further supports a direct virus-receptor interaction between
ADAM9 and EMCV or a nonenzymatic protein-protein interaction of ADAM9 with the
EMCV receptor that is required to facilitate virus entry.
Our data support that ADAM9 is a crucial protein for EMCV infection; speciﬁcally,
ADAM9 knockout cells from two mammalian species are not infected by two different
EMCV strains, reconstitution of ADAM9 permits EMCV infection, and virus replication is
unaffected by ADAM9 deﬁciency when viral RNA is transfected directly into the cytosol.
EMCV may directly bind to ADAM9, but we and others (57) have observed
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polysaccharide-related binding that may facilitate productive infection. Also, as a
disintegrin, ADAM9 is known to affect expression of other cell surface proteins (27, 38);
thus, expression of ADAM9 could lead to uncovering of another protein that is the
actual binding “receptor” protein. Since various domains and functions of ADAM9 have
been identiﬁed, future experiments will yield a fuller deﬁnition of how ADAM9 facili-
tates entry of EMCV into the cell.
In addition to ADAM9, our CRISPR-Cas9 screen in HeLa cells identiﬁed another gene,
PA2G4, which is likely involved in EMCV susceptibility (Fig. 1). The PA2G4 gene encodes
proliferation-associated protein 2G4, also known as ErbB3-binding protein 1 (EBP1),
which plays a role in cell signal transduction, transcription, and translation and has
been shown to suppress growth in certain cancers, including breast and prostate
cancers (66–72). How EBP1 affects EMCV susceptibility and its relationship to ADAM9 is
under investigation.
The discovery of ADAM9 as a surface protein required for EMCV infection has
signiﬁcant implications for our understanding of virus-host interactions and down-
stream effects of EMCV infection. We are deﬁning ADAM9’s precise role in downstream
aspects of EMCV infection. Detailed insight into the mechanism of the EMCV-ADAM9
interaction is crucial to understanding viral pathogenesis. Functional studies examining
mechanisms of EMCV binding and entry and potential for ADAM9-mediated cell
signaling and cytokine production in response to EMCV infection are currently being
explored.
MATERIALS AND METHODS
GeCKOv2 library screen. H1-HeLa cells expressing the GeCKOv2 CRISPR library (Agilent) were plated
for full coverage of the library (both pools A and B). These cells were challenged with EMCV at an MOI
of 10 until 5% of living cells remained. The cells were washed and replated for another challenge of
EMCV for conﬁrmation of resistance. gDNA was isolated by expanding the remaining cells and using the
Qiagen DNeasy Blood and Tissue kit on 2 106 cells. PCR was performed with lentiGP-1_F and
lentiGP-3_R (sequences below) with the product spanning the sgRNA guide sequences. This PCR product
was processed and sequenced using the Illumina NextSeq 500. The library screen was performed twice
for each pool of the GeCKOv2 library.
Cell viability assay. Cells were plated at 5,000 cells per well in duplicate on a 96-well ﬂat-bottomed
plate and incubated overnight at 37°C. The cells were challenged with virus at the respective MOI for 1 h
and washed with PBS, and 150 l of fresh complete medium was added to each well. The plates were
incubated for 24 h postinfection at 37°C, 10% CO2. The medium supernatants were collected, and 50 l
of fresh medium and an equal volume of room-temperature CellTiter Glo reagent (Promega G7571) were
added to each well and mixed for 2 min at 300 rpm. The reaction mixture was allowed to equilibrate for
10 min, and then 80 l of the reaction mixture was transferred to an opaque 96-well plate and the signal
was detected by a luminometer.
CRISPR KO. ADAM9 KO lines were created using CRISPR technology. HeLa cells (H1 cell line) and
293T cells with stable expression of Cas9 (53) were transiently transfected with ADAM9 CRISPR guide RNA
no. 1 (CACTGACCATCCCAATATAC) and no. 3 (CTTATGAAATTATAACTCCT) from GenScript. sgRNA guide
sequences were based on the GeCKO library designed by Feng Zhang’s laboratory at the Broad Institute;
see http://genome-engineering.org/gecko/. Cells were incubated for 3 days at 37°C to allow Cas9-
mediated gene deletion. Cells were screened by limiting-dilution cloning. Knockout clones were vali-
dated by Western blotting.
ADAM9 constructs. All mouse ADAM9 constructs were made using a Gibson assembly strategy. The
pQCXIP vector (53) was cut with NotI restriction enzyme. Two-step PCR of pcDNA mouse ADAM9 WT and
EA for full-length ADAM9 (Blobel lab) (mAdam9FL-F; mAdam9FL-R primer sequences below) was done
using Phusion high-ﬁdelity master mix (New England Biolabs M0531) as recommended by the manu-
facturer. The template for the PCR for the ΔCT mutant was the pcDNA mouse ADAM9 WT plasmid
(mAdam9FL-F; mAdam9dCT-R primer sequences below) where the reverse primer added a V5 tag as
above, and a V5-pQCXIP Gibson adaptor (V5-pQCXIP sense primer sequence below) added the stop
codon to the end of the transmembrane domain, replacing the intracellular domain. The PCR products
were puriﬁed (Qiagen). Gene assembly was done with Gibson assembly master mix (New England Biolabs
E2611) per instructions of the manufacturer into the pQCXIP retroviral backbone. Stbl3 One Shot
competent cells (ThermoFisher) were transformed with the Gibson assembly product. Minipreps were
made from single colonies of transformed bacteria and sequenced. Maxipreps of the sequenced plasmids
were made and puriﬁed using the Qiagen HiSpeed Maxi kit.
Rescue cell lines. ADAM9 rescue of the knockout cell lines was done by transduction. Retrovirus was
made using 293FT cells transfected with retroviral transfer constructs with a pQCXIP backbone (GFP,
Addgene catalog no. 73014; mouse Adam9 WT; mouse Adam9 EA; mouse Adam9 ΔCytoplasmic tail),
pMD 2.G, and VSV-G packaging plasmid using TransIT-293 transfection reagent (Mirus 2704) per protocol
(53). After 24 h, the medium was replaced with complete DMEM. At 24 h and 48 h, supernatant was
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collected (and replaced with complete DMEM as needed) and ﬁltered through an 0.45-m ﬁlter. Virus
supernatants were used immediately or frozen at 80°C in single-use aliquots.
Cell lines to be rescued were plated on 6-well plates and incubated overnight prior to retroviral
transduction. Culture medium was replaced with fresh complete DMEM, and retroviral supernatant was
added dropwise to wells. Cells were incubated at 37°C for 2 to 3 days. Transduced cells were cloned by
limiting dilution into 96-well plates and grown at 37°C. Cloned mouse ADAM9 rescue cell lines were
conﬁrmed by Western blotting and genomic DNA sequencing.
Isolation of mouse pLF and backcrossing of KO mice. All procedures conducted on mice were
approved by the Brigham and Women’s Hospital Institutional Animal Care and Use Committee. Lung
ﬁbroblasts were isolated from C57BL/6 WT and ADAM9 KO mice that were in a pure C57BL/6 background.
Primary lung ﬁbroblasts were generated from 6- to 10-week-old mice according to a protocol adapted
from Yamamoto et al. (73). Euthanized mice were washed with 90% ethanol to reduce contamination.
Whole-lung lobes were dissected and place into sterile PBS. Lungs were then submerged in 70% ethanol
for 20 s and then placed into digestion medium (DMEM with 0.25% trypsin) and cut into small pieces
using a sterile scalpel. The lung pieces were then transferred into 10 ml of digestion medium and
incubated with shaking at 37°C. After 30 min, 5 ml of cold complete DMEM (DMEM, 10% heat-inactivated
FBS, 2 mM L-glutamine, 100 U/ml penicillin, 100 g/ml streptomycin, 250 ng/ml amphotericin B) was
added, and the cells were centrifuged for 5 min at 350 g at 4°C. The cell pellet was removed and
resuspended in fresh complete DMEM. For each mouse, the lung pieces and cells were resuspended in
50 ml of complete DMEM and then plated in a 225-cm2 tissue culture ﬂask. The cells were incubated for
10 to 15 days with minimal disruption, with fresh medium added after 7 days. For the ﬁrst passage, the
cells and lung pieces were detached from the ﬂasks by scraping and separated into cells and lung pieces
with a 70-m cell strainer. The single-cell suspension was either passaged one or two times when 90%
conﬂuent in complete DMEM or used immediately for stimulation. Fibroblasts were immortalized with
SV40.
Viruses. EMCV VR-129B, EMCV-M VR-1479, and VSV strain Indiana were obtained from the American
Type Culture Collection (ATCC). IAV WSN/33 was obtained from A. L. Brass (74). HSV-1 KOS was a gift from
David Knipe (Harvard Medical School). CVB3 Nancy stocks were from Robert Finberg.
Preparation of EMCV vRNA. EMCV vRNA was isolated from ultrapure EMCV stocks using the
QIAamp viral RNA Mini kit (Qiagen) according to the manufacturer’s protocol. Viral RNA concentration
was determined by NanoDrop, and vRNA stocks were stored at 20°C until use. Cells were transfected
with viral RNA at 100 ng/well with 0.5 l of Lipofectamine 2000 (ThermoFisher Scientiﬁc catalog no.
11668027). After 1 h of transfection, the cells were washed, trypsinized, and diluted into BHK-21 cells as
described above.
Plaque assay. BHK-21 cells were plated on 12-well plates at 7 105 cells/well and incubated
overnight at 37°C to allow formation of intact monolayers. Cell growth medium was removed and
replaced with 450 l per well of fresh complete DMEM with 10% FBS. Viral supernatant samples were
thawed on ice, and 10-fold serial dilutions of virus were performed in serum-free DMEM. Diluted
supernatants were added to intact BHK-21 monolayers in duplicate at 50 l per well and mixed by gentle
plate shaking (ﬁnal dilutions between 102 and 107). Cells were incubated at 37°C for 1 h, with gentle
shaking every 20 min. After 1 h, virus dilutions were removed by aspiration, and cell monolayers were
washed with 1 PBS to remove unbound virus. An agarose overlay was added to each well and allowed
to solidify at room temperature. Plates were then incubated at 37°C for 24 h. Cells were then ﬁxed/
stained by adding crystal violet dissolved in 4% paraformaldehyde (0.5% crystal violet [(Sigma], 4%
paraformaldehyde [Sigma] in PBS [Corning]) at room temperature for at least 2 h. Overlays were
removed, and plaques were counted. PFU/ml was calculated by averaging the number of plaques in the
duplicate wells and dividing by the product of the dilution factor and volume applied to the assay wells.
Primers. Primer sequences were as follows: lentiGP-1_F, 5=-AATGGACTATCATATGCTTACCGTAACTT
GAAAGTATTTCG-3=; lentiGP-3_R, 5=-ATGAATACTGCCATTTGTCTCAAGATCTAGTTACGC-3=; mAdam9FL-F,
5=-CGCTGCAGGAATTGATCCGCGGATCCCGGGCTGCAGGAATTC-3=; mAdam9FL-R, 5=-CGAGGCCTACCGGTG
CGGCCCGAGCGGCCGCCAGTGTGATGGAT-3=; mAdam9ΔCT-R, 5=-TAATCGTCCCCCTTGTTGCGGCTGCCATT
TTCCTCTTTATCAAGGGTAAGCCTATCCCTAACCCTCTCCTCGGTCTCGATTCTACG-3= (V5 tag in bold); V5-
pQCXIP (sense), 5=-CCCTCTCCTCGGTCTCGATTCTACGTGATAGTAGGCACCGGTAGGCCTCGTACGC-3=.
Western blotting. Following trypsinization, cells were lysed with RIPA buffer with protease inhibitor
cocktail (Sigma P8340) incubated at room temperature for 10 min. The lysate was cleared by centrifu-
gation at 15,000 rpm for 10 min to remove cell debris. The concentration of the lysates was determined
by BCA assay (ThermoFisher PI23227). Twelve percent precast gels (Bio-Rad 4561044) were loaded
equally with lysate and run at 80 V. The proteins were transferred to a PVDF membrane (Bio-Rad
1620219) with a semidry transfer system (Bio-Rad 1703940) for 60 min at 25 V (300 mA maximum). The
membrane was blocked with 3% BSA or 5% nonfat dry milk in Tris-buffered saline with 0.1% Tween 20
(TBS-T) for at least 1 h. Incubation of the membrane with primary antibodies was done overnight at 4°C
with rocking/shaking. Membranes were washed three times with TBS-T. Secondary HRP-conjugated
antibodies were diluted in TBS-T, added to membrane, and incubated for 1 to 2 h at room temperature
with shaking. Membranes were washed ﬁve times with TBS-T and visualized with ECL (Thermo Scientiﬁc
34080) and exposed on ﬁlm as needed. To determine loading, the membrane was stripped with Restore
Plus Western stripping buffer (Thermo Scientiﬁc 46430) for 10 min and washed twice with TBS-T. The
membrane was blocked again in 3% BSA in TBS-T for at least 1 h. Anti-actin HRP conjugate was added
in TBS-T and incubated for1 h at room temperature with shaking. The membrane was then washed ﬁve
times with TBS-T and visualized as above. Antibodies used were goat anti-mouse ADAM9 (R&D Systems
AF949; 1:1,000 dilution, 3% BSA blocking buffer), rabbit anti-human ADAM9 (Cell Signaling 2099; 1:1,000
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dilution, 5% milk blocking buffer), anti-actin HRP conjugate (Santa Cruz sc-1616; 1:2,000 dilution, 3% BSA
blocking buffer), anti-goat IgG HRP (1:2,000 dilution; R&D Systems HAF109), and anti-rabbit IgG HRP
(1:5,000 dilution; Vector Labs PI1000).
Statistical analysis. Differences in the means of data were compared using unpaired, two-tailed
Student’s t test. ANOVA was used when comparing multiple values. Signiﬁcant differences were assumed
for P values of 0.05. All statistical analyses were performed using GraphPad Prism software (version
7.0d; GraphPad, San Diego, CA).
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